The Technical Analyst
Clearpoint Neuro Inc [CLPT]
Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
Clearpoint Neuro Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.94% $5.26
America/New_York / 26 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 141.90 mill |
| EPS: | -0.900 |
| P/E: | -5.84 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 26.98 mill |
| Avg Daily Volume: | 0.154 mill |
| RATING 2024-04-26 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -5.84 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.03x |
| Company: PE -5.84 | industry: PE 222.16 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 4.91 - 5.61 ( +/- 6.65%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-01 | Fletcher R John | Buy | 850 | Common Stock |
| 2024-04-01 | Girin Pascal E R | Buy | 1 056 | Common Stock |
| 2024-04-01 | Liau Linda M. | Buy | 436 | Common Stock |
| 2024-04-01 | Richards Timothy T. | Buy | 1 640 | Common Stock |
| 2024-03-11 | Stigall L. Jeremy | Buy | 16 583 | Restricted Stock Units |
| INSIDER POWER |
|---|
| 55.18 |
| Last 96 transactions |
| Buy: 810 905 | Sell: 147 333 |
Forecast:
16:00 - $5.26
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $5.26
Forecast 2: 16:00 - $5.26
Forecast 3: 16:00 - $5.26
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $5.26 (-0.94% ) |
| Volume | 0.168 mill |
| Avg. Vol. | 0.154 mill |
| % of Avg. Vol | 109.03 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CLPT
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CLPT
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
Latest Press Releases
2024-04-16 16:05:00 - Press Release
Clearpoint Neuro Congratulates Its Partner Aviadobio On First Patient Treated In Its Aspire-ftd Clinical Trial Evaluating Avb-101 For Frontotemporal Dementia With Grn Mutations
Clearpoint neuro platform and smartflow cannula to be used by all centers in aviadobio's aspire-ftd gene therapy trial treating frontotemporal dementia
2024-04-08 09:15:00 - Press Release
Shareholder Alert: Purcell & Lefkowitz Llp Announces Shareholder Investigation Of Clearpoint Neuro, Inc. (nasdaq: Clpt)
New york , april 8, 2024 /prnewswire/ -- purcell & lefkowitz llp announces that it is investigating clearpoint neuro, inc. (nasdaq: clpt) on behalf of the company's shareholders. the investigation seeks to determine whether clearpoint neuro's directors breached their fiduciary duties in connection with recent corporate actions.
2024-03-19 08:07:00 - Press Release
Clearpoint Neuro Congratulates Its Partner Ptc Therapeutics On Completion Of Biologics License Application Submission To Fda For Upstaza™ as A Treatment For Aadc Deficiency
Solana beach, calif., march 19, 2024 (globe newswire) -- clearpoint neuro, inc. (nasdaq: clpt) (the “company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today congratulates its partner ptc therapeutics on completion of its bla submission to the u.s. food and drug administration (fda) for the approval of upstaza™ (eladocagene exuparvovec), an investigational treatment for aadc deficiency.
2024-03-12 16:05:00 - Press Release
Clearpoint Neuro Reports Fourth Quarter And Full-year 2023 Results
Solana beach, calif., march 12, 2024 (globe newswire) -- clearpoint neuro, inc. (nasdaq: clpt) (the “company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its fourth quarter and full-year ended december 31, 2023.
2024-03-01 16:05:00 - Press Release
Clearpoint Neuro To Announce Fourth Quarter And Full Year 2023 Results March 12, 2024
Solana beach, calif., march 01, 2024 (globe newswire) -- clearpoint neuro, inc. (nasdaq: clpt) (the “company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2023 fourth quarter and full year on tuesday, march 12th, after the market close.
Latest News
2024-04-25 02:30:00 - Seeking Alpha
ClearPoint Neuro: Macro-Induced Multiple Compression
2024-03-27 09:36:07 - Zacks Investment Research
Why ClearPoint Neuro (CLPT) Stock Might be a Great Pick
ClearPoint Neuro (CLPT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
2024-03-12 23:39:06 - Seeking Alpha
ClearPoint Neuro, Inc. (CLPT) Q4 2023 Earnings Call Transcript
2024-03-12 18:41:03 - Zacks Investment Research
ClearPoint Neuro, Inc. (CLPT) Reports Q4 Loss, Tops Revenue Estimates
ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.18 per share a year ago.
2024-03-12 11:41:07 - Zacks Investment Research
ClearPoint's (CLPT) Prism System Favored by Latest Study
ClearPoint's (CLPT) Prism Neuro Laser Therapy System is likely to provide an integrated solution for precise and more efficient laser interstitial thermal therapy.
2024-03-07 07:16:12 - InvestorPlace
The Top 7 Under-$15 Stocks to Buy in March 2024
Fifteen bucks won't go too far these days – unless you want to invest in these under-$15 stocks to buy. Inflation growth may be falling, which obscures the real fact that pricing today for goods and services remains higher than just two years ago.
2024-03-01 16:05:00 - GlobeNewsWire
ClearPoint Neuro to Announce Fourth Quarter and Full Year 2023 Results March 12, 2024
SOLANA BEACH, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2023 fourth quarter and full year on Tuesday, March 12th, after the market close.
2024-02-26 12:05:14 - Zacks Investment Research
ClearPoint Neuro (CLPT) Gets FDA's Nod for New Software
ClearPoint Neuro's (CLPT) receipt of the FDA's latest approval is likely to provide fast, peri-procedural segmentation of the cortical structures of the brain.
2024-02-15 16:19:32 - InvestorPlace
The 3 Up-and-Coming Stocks That Could Make Your February Unforgettable
Finding a quality up-and-coming stock is a tricky proposition, but doubly so now that we're well past the ZIRP-era “stocks go up” sentiment. In the past, you could throw capital at any up-and-coming stock and have a pretty good chance of generating returns.
2024-02-09 06:25:00 - InvestorPlace
3 Strong Buy Healthcare Stocks to Add to Your February Must-Watch List
Healthcare stocks are one of the best sectors to capture long-term innovation and sector strength. After all, healthcare needs are perennial, especially as the global population lives longer and can generally afford more than the bare minimum of care.